We are live on ! Find out more
BCLI

BRAINSTORM CELL THERAPUTC
BCLI

Delisted

BCLI was delisted on the 17th of July, 2025.

Back to rankings

47 hedge funds and large institutions have $2.19M invested in BRAINSTORM CELL THERAPUTC in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

6,500% more call options, than puts

Call options by funds: $66K | Put options by funds: $1K

108% more capital invested

Capital invested by funds: $1.05M → $2.19M (+$1.14M)

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

2% more funds holding

Funds holding: 46 → 47 (+1)

0% more ownership

Funds ownership: 0.55% → 0.55% (+0%)

50% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 10

Holders
47
Holders Change
+1
Holders Change %
+2.17%
% of All Funds
0.68%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
5
Reduced
10
Closed
6
Calls
$66K
Puts
$1K
Net Calls
+$65K
Net Calls Change
+$90K

Top Buyers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
+$40.8K
2
KWA
Kingswood Wealth Advisors
California
+$29.7K
3
BlackRock
BlackRock
New York
+$8.42K
4
Jane Street
Jane Street
New York
+$6.87K
5
Group One Trading
Group One Trading
Illinois
+$2.42K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$23K
2
VF
Virtu Financial
New York
-$19K
3
Vanguard Group
Vanguard Group
Pennsylvania
-$8.18K
4
Barclays
Barclays
United Kingdom
-$6.31K
5
ZIG
Zullo Investment Group
Pennsylvania
-$4.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$6.77K – – –
TRCT
27
Tower Research Capital (TRC)
New York
$6.22K -$2.65K -482 -40%
Osaic Holdings
28
Osaic Holdings
Arizona
$5.89K -$82 -15 -2%
CCMW
29
Cypress Capital Management (Wyoming)
Wyoming
$5.65K – – –
IFAM
30
Institutional & Family Asset Management
Colorado
$3.39K – – –
SPIA
31
Steward Partners Investment Advisory
New York
$2.37K – – –
BSB
32
Bangor Savings Bank
Maine
$2.26K – – –
Simplex Trading
33
Simplex Trading
Illinois
$2K +$1.48K +269 New
UBS Group
34
UBS Group
Switzerland
$1.41K – – –
VAG
35
VisionPoint Advisory Group
Texas
$1.1K – – –
CA
36
Clearstead Advisors
Ohio
$822 +$550 +100 New
EWA
37
EverSource Wealth Advisors
Alabama
$803 – – –
CWM
38
Cranbrook Wealth Management
Michigan
$565 +$368 +67 New
Bank of America
39
Bank of America
North Carolina
$564 -$16 -3 -4%
DJSG
40
D.J. St. Germain
Massachusetts
$282 – – –
BNP Paribas Financial Markets
41
BNP Paribas Financial Markets
France
$206 – – –
WIM
42
Westside Investment Management
California
$112 – – –
CA
43
CoreCap Advisors
Michigan
$75 +$49 +9 New
JP Morgan Chase
44
JP Morgan Chase
New York
$60 +$11 +2 +40%
MSFP
45
Mark Sheptoff Financial Planning
Connecticut
$56 – – –
VF
46
Virtu Financial
New York
– -$19K -4,732 Closed
Barclays
47
Barclays
United Kingdom
– -$6.31K -1,542 Closed
ZIG
48
Zullo Investment Group
Pennsylvania
– -$4.4K -1,074 Closed
HighTower Advisors
49
HighTower Advisors
Illinois
– -$3K -683 Closed
AWM
50
Able Wealth Management
New Jersey
– -$524 -128 Closed
1
2
3

BCLI Hedge Fund Activity: Q1 2024 in Review

47 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q1 2024, worth a combined $2.19M — up 108% from $1.05M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new BCLI positions and 6 closed out — a net gain of 1 holder — while 5 added to existing stakes and 10 trimmed.

The largest buyer was GSA Capital Partners, opening a new position worth an estimated $40.8K. The largest seller was Morgan Stanley, cutting an estimated $23K.

  • 47 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q1 2024, up from 46 in Q4 2023.
  • Funds reported $2.19M of BRAINSTORM CELL THERAPUTC stock for Q1 2024, up 108% quarter-over-quarter.
  • 7 funds opened new BRAINSTORM CELL THERAPUTC positions in Q1 2024 and 6 closed out, a net change of +1 holder.
  • The largest BRAINSTORM CELL THERAPUTC buyer in Q1 2024 was GSA Capital Partners, an estimated $40.8K added.
  • The largest BRAINSTORM CELL THERAPUTC seller in Q1 2024 was Morgan Stanley, an estimated $23K sold.

Based on aggregated 13F filings for Q1 2024.